JPX:4570

Immuno-Biological Laboratories Co., Ltd. · JPX · Healthcare · JPY · FY for 2026

Figures on this page computed 2026-11-08 13:29 UTC

Last close

n/aJPY

Market data

25.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
JPY
- computed
- Computed from the filing for 2026
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
32.7%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
26.6%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
JPY
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
JPY
- computed

Price is the furthest below its sector's middle: 0.24 against 0.37 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one yen

lens 1 of 9

After what it costs to make

69.7%

After running the business

28.0%

After interest and tax

32.7%

After what it must reinvest

26.6%

Kept after the dividend

n/a

after what it costs to make, 69.7% of sales; after running the business, 28.0% of sales; after interest and tax, 32.7% of sales; after what it must reinvest, 26.6% of sales

The five stops

4 of 5 read

After what it costs to make700,280,00069.7%
After running the business281,278,00028.0%
After interest and tax329,015,00032.7%
After what it must reinvest267,677,00026.6%
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2026

Sales1,004,987,000
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY
After what it costs to make700,280,000
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY
After running the business281,278,000
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY
After interest and tax329,015,000
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY
After what it must reinvest267,677,000
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY
Kept after the dividendn/a
Not held.
Source
computed
Statement
income
Fiscal year
2026
Reported in
JPY